BioSpace News Archive

I-Mab today announced that the first patient had been dosed in its China phase 2 study (NCT05145907) of efineptakin alfa.

Kintara Therapeutics, Inc. today announced that a multiyear research grant from Luxembourg National Research Fund (FNR) and Cancer Foundation Luxembourg has been awarded to Doctor Anna Golebiewska Ph.D.

OncoHost today announced results from its ongoing multicenter clinical trial, PROPHETIC.

Biotechnology company Evolved by Nature announced today that sister company Silk Medical Aesthetics has received Investigational Device Exemption (IDE) approval from the FDA to initiate a pivotal clinical trial for its new dermal filler for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.

MYND Life Sciences Inc. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced that it has entered into Collaborative Research Agreement (the “Agreement”) with the University of British Columbia (“UBC”) focussing on Novel Therapies for Neurological Diseases.

insitro, a machine learning-driven drug discovery and development company, today announced the expansion of its leadership team with the appointments of several industry leaders.

Jaguar Health, Inc., under its Jaguar Animal Health tradename for the veterinary market, announced that the company is hosting a treatment forum for veterinarians about chemotherapy-induced diarrhea in dogs on Sunday, January 16 from 6 p.m. - 8 p.m.

New research in the January 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined the impact of septic shock on people with hematologic malignancies, finding 67.8% died in fewer than 28 days and only 19.4% remained alive after 90 days.

Chronus Health, a point-of-care diagnostics company, announced today that it has raised $22 million Series A financing led by Tarsadia Investments with participation from Monta Vista Capital, SOSV, Savantus Ventures, and an undisclosed strategic investor.

Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2021 financial results ahead of its participation at the 40th Annual J.P. Morgan Healthcare Conference occurring January 10-13, 2022.